Publications by authors named "GR Lichtenstein"
Article Synopsis
- Interleukin-23 inhibition is a promising treatment for ulcerative colitis, and guselkumab serves as a potent inhibitor targeting this pathway, aiming to assess its safety and effectiveness for patients who have not responded to traditional therapies.
- The study included two phase 3 trials where adults with moderate to severe active ulcerative colitis were randomly assigned to receive guselkumab or a placebo, with a focus on clinical remission as the main outcome at specific time points.
- Results showed that a significantly higher number of patients receiving guselkumab achieved clinical remission compared to those on placebo, highlighting its potential as an effective therapy for managing ulcerative colitis.
Endoscopy plays a key role in diagnosis, monitoring of disease activity, assessment of treatment response, dysplasia surveillance, postoperative evaluation, and interventional therapy for patients with inflammatory bowel disease (IBD). Clinical practice patterns in the endoscopic management of IBD vary. A panel of experts consisting of IBD specialists, endoscopists, and GI pathologists participated in virtual conferences and developed this modified Delphi-based consensus document to address endoscopic aspects of IBD management.
View Article and Find Full Text PDFExploring the Use of Biosimilars to Treat Patients With Inflammatory Bowel Disease.
Gastroenterol Hepatol (N Y)
July 2024
Examining Pharmacoequity in Older Inflammatory Bowel Disease Patients.
Gastroenterol Hepatol (N Y)
August 2024
Exploring Diets Beyond the Low-FODMAP Diet to Treat Patients With IBS.
Gastroenterol Hepatol (N Y)
August 2024
Article Synopsis
- Infliximab (IFX) biosimilars are used to treat inflammatory bowel disease (IBD) and are generally cheaper than original IFX, but concerns about switching between the two products persist.
- A systematic review of studies conducted between 2012 and 2022 found that switching from originator to biosimilar IFX did not significantly affect treatment effectiveness or safety, with reported adverse events being consistent with known profiles.
- Most studies concluded that outcomes for clinical effectiveness, patient-reported results, and safety after switching were comparable to those of the original IFX, although there is limited data on patients who switch multiple times.
Exploring Cardiovascular Comorbidities and Inflammatory Bowel Disease.
Gastroenterol Hepatol (N Y)
April 2024
Applications of Artificial Intelligence in Esophageal Diseases.
Gastroenterol Hepatol (N Y)
March 2024
Exploring Vaccination in Patients With Inflammatory Bowel Disease.
Gastroenterol Hepatol (N Y)
February 2024
Marking Our Twentieth Year of Covering Gastroenterology and Hepatology.
Gastroenterol Hepatol (N Y)
January 2024
Managing Older Patients Who Have Inflammatory Bowel Disease.
Gastroenterol Hepatol (N Y)
October 2023
Examining Janus Kinase Inhibitors for the Treatment of Inflammatory Bowel Disease.
Gastroenterol Hepatol (N Y)
December 2023
Evidence-Based Approach to Chronic Antibiotic Refractory Pouchitis: A Review.
Dis Colon Rectum
June 2024
Background: Chronic antibiotic refractory pouchitis after restorative proctocolectomy with IPAA, characterized by at least 4 weeks of pouchitis symptoms that have not responded to standard antibiotic therapy, presents a therapeutic challenge for patients and health care providers.
Objective: The aim of this narrative review was to summarize the current evidence regarding the management of chronic antibiotic refractory pouchitis.
Data Sources: Studies were identified through a search of the PubMed database from the National Library of Medicine.
Background & Aims: Evaluating cardiovascular safety of sphingosine 1-phosphate (S1P) receptor modulators is warranted due to S1P receptor expression on cardiomyocytes and vascular endothelial cells. This analysis reports the cardiovascular safety of ozanimod, an S1P receptor modulator, in patients with moderately to severely active ulcerative colitis from the phase 3 True North (TN) and open-label extension (OLE).
Methods: All patients who received ozanimod in TN (n = 796) and all eligible TN patients who entered the OLE (n = 823) were included.
Examining Race and Ethnicity in Patients With Inflammatory Bowel Disease.
Gastroenterol Hepatol (N Y)
May 2023
Small Molecule and Biologic Therapies for Ulcerative Colitis.
Gastroenterol Hepatol (N Y)
August 2023
Highlights in Ulcerative Colitis From the 18th Congress of ECCO: Commentary.
Gastroenterol Hepatol (N Y)
April 2023
Breath Testing for Small Intestinal Bacterial Overgrowth and Intestinal Methanogen Overgrowth.
Gastroenterol Hepatol (N Y)
March 2023